Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

272
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

08/21/2012 | 06:13pm US/Eastern
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on JOHNSON & JOHNSON
01:51a AbbVie to buy Pharmacyclics for $21 billion to boost cancer drugs pipeline
01:51a AbbVie to buy Pharmacyclics for $21 billion to boost cancer drugs pipeline
01:25a JOHNSON & JOHNSON : What the other papers say this morning
12:03aDJAbbVie to Buy Pharmacyclics in $21 Billion Deal -- 2nd Update
03/04DJAbbVie to Buy Pharmacyclics in $21 Billion Deal -- Update
03/04 JOHNSON & JOHNSON : Report: J&J close to deal to buy partner Pharmacyclics
03/04DJJohnson &Johnson Near Deal for Drugmaker Pharmacyclics -FT
03/04 JOHNSON & JOHNSON : Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on R..
03/04 JOHNSON & JOHNSON : Hillsborough OKs $2.1 million to bring Johnson & Johnson job..
03/04 JOHNSON & JOHNSON : Incentive money just one cost of landing Johnson & Johnson
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF